Shopping Cart
Remove All
Your shopping cart is currently empty
Cendakimab
(Synonyms: RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308) Copy Product Info
🥰Excellent
Synonyms: RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308
Catalog No. T76942 Copy Product Info
🥰Excellent
Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.
Cas No. 2151032-62-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | In Stock | In Stock | |
| 5 mg | $463 | In Stock | In Stock | |
| 10 mg | $742 | - | In Stock | |
| 25 mg | $1,120 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis. |
| Targets & IC50 | IL-13Rα1:352 pM, aglycosylated IL-13:17 pM, IL-13α2:631 pM, glycosylated IL-13:37 pM |
| In vitro | Cendakimab is an IgG1k humanized monoclonal antibody that recognizes IL-13 and inhibits its binding to IL-13 receptor-specific subtypes (IL-13-Rα1 and IL-13-Rα2) with an IC50 of 352 pM and 631 pM, respectively, as determined by ELISA. [2] cendakimab inhibited glycosylated and non-glycosylated IL-13-induced STAT6 activity in a dose-dependent manner with IC50 of 37pM and 17pM, respectively. [1] |
| In vivo | In a mouse model of asthma, Cendakimab dose-dependent inhibited AHR (maximum inhibition 70.5%) and IL-13-dependent gene expression, and maximal inhibition of Muc5ac and AMCase activity was 70.7% and 54.2%, respectively. [2] |
| Synonyms | RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-13 |
| Molecular Weight | 146.44 kDa |
| Cas No. | 2151032-62-9 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Cendakimab chemical structure | Cendakimab in vivo | Cendakimab in vitro | Cendakimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.